Yeah, this part of the Movie is Nauseating.
BofA On 3 Coronavirus Vaccine Frontrunners, The Remdesivir Opportunity And Antibodies
The markets are ready for a steady flow of updates from COVID-19 drug and vaccine developers as the world races to contain the pandemic and bring back some semblance of normalcy.
Against this backdrp, BofA Securities issued an update to its view on COVID-19 market opportunities.
Mixed Results From COVID-19 Market: The market remains dynamic but the results have been mixed, analyst Geoff Meacham said in a Friday note. Hydroxycholoroquine and Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Kevzara faced setbacks, the analyst said.
The FDA revoked the Emergency Use Authorization for hydroxycholorquine, and a Kevzara study in COVID-19 was stopped by Regeneron following a failed late-stage trial, he said.
Yet there were meaningful wins, with vaccine and antibody development starting to accelerate, Meacham said.
"We recognize recent datasets have been early and necessarily incomplete — with much still unknown about the virus — resulting in outsized market movements for individual developers and the broader market."
An antibody is unlikely to arrive before the fall, with any broadly available vaccine to follow by the second half of 2021 at best, the analyst said.
With the ongoing progress, Meacham said he expects continued positive momentum through the summer.
https://www.yahoo.com/news/bofa-3-coronavirus-vaccine-frontrunners-164736601.html